IRLAB Therapeutics — EMA alignment on mesdopetam Phase III plans
IRLAB has bolstered the value of its lead programme, mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following confirmation that the European...
221 Views
IRLAB Therapeutics — Pirepemat stumbles in Phase IIb study
IRLAB has announced top-line results for its Phase IIb trial assessing pirepemat’s potential to improve balance and reduce falls in Parkinson’s...
210 Views
IRLAB Therapeutics — Next steps laid out for IRL757
IRLAB has confirmed that clinical candidate IRL757, which has been designed to address apathy in patients with neurodegenerative conditions, will...
226 Views